Search Results - technology+classifications+%3e+therapeutic+modalities+%3e+therapeutic+delivery+platforms

124 Results

Sort By:

Dendrimer-conjugated GCPII Inhibitors to Delay Loss of Muscle Mass and Strength

Value Proposition· GCPII inhibitor has a low IC50 (<5 nM), suggesting greater potency and less systemic toxicity.· Functional improvements after treatment include 95% preservation of muscle mass, 96% preservation of grip strength, 25% greater isometric force.· Decreased decline in neuromuscular transmission compared to control. Technology...

Published: 3/13/2026 | Inventor(s): Barbara Slusher, Yu Su, Kannan Rangaramanujam

Keywords(s):

Category(s): Clinical and Disease Specializations > Musculoskeletal > Muscle Atrophy, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms

Gene therapy for neurofibromatosis type 1

JHU Ref #: C18504Value Proposition· Targets direct genetic cause of NF1 rather than only symptoms.· Improves therapeutic options for NF1 patients.· AAV vector is one of the safest viral vectors for gene therapy.· Market for NF1 gene therapies is quite open.Unmet NeedNeurofibromatosis type 1 (NF1) affects approximately 1 in 2,500...

Published: 3/13/2026 | Inventor(s): Renyuan Bai, Verena Staedtke

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities > Gene Therapies, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms

Bicistronic Genes and Fusion Proteins for Immune Activation

Value Proposition:· Dual specific targeting for improved full T-cell and amplification.· Interchangeable protein components can be customized for cancer, infectious disease, and autoimmune disorder therapies.· Deliverable by nanoparticles into cells in vivo, in vitro, and ex vivo for immune activation.Unmet Need:Immunotherapy is a rapidly...

Published: 3/13/2026 | Inventor(s): Jordan Green, Joanna Yang, Stephany Tzeng, Jamie Spangler

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities > Gene Therapies, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Proteins, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Research Tools > Vectors & Plasmids, Technology Classifications > Research Tools > Proteins, Ligands & Receptors, Technology Classifications > Research Tools > Nucleic Acids

Non-intuitive combination of drug delivery carriers of the same drug for synergistic growth delay of solid tumors

Non-intuitive combination of drug delivery carriers of the same drug for synergistic growth delay of solid tumorsJHU Ref #: C15411 Unmet NeedCancer is the second leading cause of death in the United States, with an estimated 1.8 million cases having been diagnosed and 606,520 people having succumbed to the disease in 2020. The most common cancer diagnosis...

Published: 3/13/2026 | Inventor(s): Stavroula Sofou, Alaina Howe

Keywords(s): Breast Cancer, Cancers, Disease Indication, Drug Delivery Vehicle, Nanoparticles, Therapeutic Matter, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Clinical and Disease Specializations > Oncology

Methods for High-throughput Identification of Genomic Harbors for Transgene Expression in Cells

Value Proposition:· High-throughput screening of loci for exogenous gene insertion · Quantifies expression level of exogenous genes in cell type of interest Unmet Need· Exogenous or synthetic genes that are inserted into the genome serve various purposes, depending on the context and goals of the genetic modification. This includes...

Published: 3/13/2026 | Inventor(s): Reza Kalhor, Jinwoo Jun, Kathleen Leeper

Keywords(s):

Category(s): Technology Classifications > Research Tools > Assays, Technology Classifications > Research Tools > Nucleic Acids, Technology Classifications > Research Tools > Vectors & Plasmids, Technology Classifications > Research Tools > Bioinformatics, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities > Gene Therapies

Ion-paired Crystal Formulations for the Treatment and Prevention of Ocular Infection

Unmet Need· Ocular infections are quite common, with millions of cases occurring each year. Without proper treatment, infections can lead to serious complications (e.g., blindness).· The current standard of care requires patients to self-administer eye drops at least 3 times daily to maintain therapeutic concentration levels; in severe...

Published: 3/13/2026 | Inventor(s): Matthew Appell, Laura Ensign

Keywords(s):

Category(s): Clinical and Disease Specializations > Ophthalmology, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms

Water-based Microcrystal Formulations for Sustained Release

Non-Confidential Title· Low-volume, extended-release therapeutics for neuroprotection JHU Ref #: C17657Value Proposition· High concentration, low volume, solvent-free microcrystal preparation of neuroprotective compounds.· Facilitates direct delivery and sustained release of neuroprotective compounds to areas where low volumes are...

Published: 3/13/2026 | Inventor(s): Laura Ensign, Justin Hanes, Tung Heng Hsueh

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms

Combinations of ASOs for the Modulation of SMN Expression in SMA Patients

Unmet NeedSpinal muscular atrophy (SMA) is a devastating neuromuscular disease that predominantly affects children and is the most common cause of hereditary infant mortality. The disease is caused by low levels of survival motor neuron (SMN) protein, due to recessive mutations in the SMN1 gene. Importantly, the copy number variation of SMN2, a homologous...

Published: 3/13/2026 | Inventor(s): Charlotte Sumner, Constantin d'Ydewalle, Frank Rigo, C. Bennett

Keywords(s): CNS and Neurological Disorders, Combination, Disease Indication, Drug Delivery Vehicle, Muscle Atrophy, Muscular Disorders, Neurodegenerative Diseases, Peptides/Prodrugs, Single, Targeted Therapy, Therapeutic Matter, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations > Neurology > Motor Neuron Diseases, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities > Proteins

Co-assembling Peptide Hydrogels

The compositions and methods disclosed herein pertain to the manufacture and use of hydrogels. The disclosed compositions and methods pertain to hydrogels capable of induction by a variety of methodologies, such as by pH, salt and/or mixing. Such hydrogels are capable of self- or co-assembly and while doing so, may entrap a variety of bioactive agents...

Published: 3/12/2026 | Inventor(s): Yihua Yu, Sivakumar Ramachandran, Peter Flynn, Yiider Tseng

Keywords(s): Drug Delivery Vehicle, Hydrogel, Therapeutic Matter, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities

A peptide that forms pores in membranes at acidic pH for the delivery of macromolecules through the plasma membrane or endosomes, or the lysis of cancer cells.

Unmet Need There are significant roadblocks to the routine delivery of macromolecules such as proteins, peptides, imaging agents, polysaccharides and more to the cytosol of mammalian cells. While most macromolecules are easily directed to existing cellular uptake mechanisms, they are often trapped in endosomal pathways leading to lysosomal degradation...

Published: 3/12/2026 | Inventor(s): Kalina Hristova, Gregory Wiedman, William Wimley, Sarah Kim

Keywords(s): Biologics, Drug Delivery Vehicle, Peptide, Peptides/Prodrugs, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities

1 2 3 4 5 6 7 8 9 10 ...